In a significant development for the biotechnology sector, Clearmind Medicine Inc. (NASDAQ: CMND) has received a notice of allowance for a patent covering its innovative approach to mitigating binge behavior, contributing to its arsenal in the fight against alcohol use disorder (AUD). As of the time of writing, Clearmind s shares are trading at $0.92, marking a noteworthy moment in the company s ongoing journey.Despite this positive momentum, Clearmind s stock has exhibited a relatively softer performance year-to-date compared to the CSIMarkets index, which serves as a benchmark for suppliers in the industry. The company s shares have seen a 4.42% decrease this year, trailing behind the performance of its cu...
: The metabolic disorder obesity continues to pose significant health challenges worldwide, underscoring the urgent need for innovative therapeutic solutions. Recently, a study spearheaded by Clearmind Medicine Inc., a clinical-stage biotech company, has unveiled groundbreaking findings on the potential of 5-methoxy-2-aminoindane (MEAI) as a novel weight loss drug. This article delves into the methodology, results, and implications of this study, highlighting MEAI s capability to address obesity effectively. Clearmind Medicine Inc. (Nasdaq: CMND; FSE: CWY0) is at the forefront of developing psychedelic-derived therapeutics for under-treated health conditions. In a recent pivotal study, researchers at the Ob...
Clearmind Medicine Expands Global Reach with Partnership for Alcohol Substitute Beverage, Secures Exclusive Rights for PTSD Treatment, and Announces Licensing Agreement for Mental DisordersVancouver, Canada - Clearmind Medicine Inc., a clinical-stage biotech company focused on the discovery and development of novel psychedelic-derived therapeutics, is making significant strides in its mission to address under-treated health problems. The company has recently signed several strategic agreements and licensing partnerships that showcase its commitment to expanding its product portfolio and improving mental health treatment.To kickstart its international expansion, Clearmind Medicine has entered into a strategic...
Innovative Treatment for Alcoholism: Clearmind Medicine s IND Approval for MEAI-Based CMND-100 Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) a Vancouver-based clinical-stage biotech company is revolutionizing the landscape of treatments for Alcohol Use Disorder (AUD). With a focus on the exploration and development of novel psychedelic-derived therapeutics, Clearmind Medicine announced a pivotal milestone: the U.S. Food and Drug Administration (FDA) has approved their Investigational New Drug (IND) application. This endorsement will facilitate the commencement of a Phase I/IIa clinical trial for their proprietary MEAI-based (5-methoxy-2-aminoindane) oral capsule, CMND-100, in the United States. T...
Clearmind Medicine Inc., a clinical-stage biotech company, has made significant strides in revolutionizing the non-alcoholic beverages market with its groundbreaking psychedelic-based drink. Alongside this achievement, Clearmind also announces advancements in its proprietary MEAI-based alcohol substitute beverage program. These developments have the potential to transform the $13 billion non-alcoholic beverages market and address under-treated health problems. In this article, we will outline the facts surrounding these advancements and assess their impact on Clearmind Medicine Inc.Clearmind s Psychedelic-Based Drink:Clearmind Medicine Inc. has shaken the non-alcoholic beverages market with its innovative ps...
Clearmind Medicine Inc., a Vancouver-based clinical-stage biotech company, has recently announced a significant development in the field of psychedelic-derived therapeutics to address the under-treated health issue of post-traumatic stress disorder (PTSD). The company has secured exclusive global rights to further develop, manufacture, and commercialize innovative compounds invented by renowned professors from the Hebrew University of Jerusalem.The exclusive patent licensing agreement, signed with Yissum Research Development Company, provides Clearmind Medicine with a transformative opportunity to revolutionize the treatment of mental health conditions, specifically PTSD. Professors Rami Yaka, Ahmed Masaewa,...
Clearmind Medicine Inc., a clinical-stage biotech company, has recently achieved significant milestones in its pursuit of using novel psychedelic-derived therapeutics to address major health challenges. This article explores the latest developments in Clearmind Medicine s clinical trial for alcohol use disorder (AUD) patients and its exclusive licensing agreement for cocaine addiction treatment, while also discussing the outcomes of the Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the company s CMND-100 compound.1. Phase I/IIa Clinical Trial Approval for Alcohol Use Disorder Treatment:Clearmind Medicine has received approval from the Israeli Ministry of Health to commence its pha...
Clearmind Medicine Inc. recently announced a significant milestone in their mission to revolutionize mental health treatment. The biotech company completed a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the clinical trial of their proprietary MEAI-based, CMND-100 compound for the treatment of Alcohol Use Disorder (AUD). This groundbreaking meeting represents a key stepping stone in Clearmind Medicine s vision to develop novel psychedelic-derived therapeutics to address under-treated health problems.Exploring the Potential of Psychedelic Therapy:Psychedelic therapy has shown promising results in addressing various mental health conditions, including addiction. Clearmind Medicine ...
Clearmind Medicine: Achieving Breakthrough Results in Cocaine Addiction Treatment Tel Aviv, Israel / Vancouver, Canada, Dec. 05, 2023 - Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY), known for its focus on the discovery and development of novel psychedelic-derived therapeutics to address under-treated health problems, has proudly announced a major milestone in addiction treatment. The company has achieved positive results in their revolutionary treatment targeting cocaine addiction, thanks to their groundbreaking psychedelic molecule, MEAI. Addiction, particularly to substances such as cocaine, continues to plague societies worldwide. Traditional treatment methods, while effective for some,...
Clearmind Medicine Raises US$2.25 Million in US-only Public Offering Tel Aviv, Israel / Vancouver, Canada, Sept. 14, 2023 - Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY), a biotech company dedicated to developing innovative psychedelic-derived treatments for under-treated health issues, has successfully priced its public offering at approximately US$2.25 million. This offering, conducted solely in the United States, is expected to generate substantial proceeds for the Company after deducting placement agent fees and other expenses. The public offering comprises 7,500,000 common shares and also includes pre-funded warrants and common warrants. The common warrants will be immediately e...
Sources:
Clearmind Medicine Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Clearmind Medicine Inc’s corporate clients.
For your research, we’ve provided 9 tables on Clearmind Medicine Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
